[Journal logo]

Volume 69 
Part 9 
Pages m498-m499  
September 2013  

Received 16 July 2013
Accepted 10 August 2013
Online 17 August 2013

Key indicators
Single-crystal X-ray study
T = 293 K
Mean [sigma](C-C) = 0.009 Å
Disorder in main residue
R = 0.077
wR = 0.233
Data-to-parameter ratio = 12.2
Details
Open access

cis-Diaquatetrakis(1-butyl-1H-imidazole-[kappa]N3)nickel(II) dichloride

aDepartment of Physics, S. M. K. Fomra Institute of Technology, Thaiyur, Chennai 603 103, India,bDepartment of Chemistry, Pondicherry University, Pondicherry 605 014, India, and cDepartment of Physics, Presidency College (Autonomous), Chennai 600 005, India
Correspondence e-mail: a_sp59@yahoo.in

In the title compound, [Ni(C7H12N2)4(H2O)2]Cl2, the nickel(II) ion has a distorted octahedral coordination environment. It is surrounded by three N atoms and one O atom occupying the equatorial plane, and one N and one O atom in the axial positions. The imidazole ring systems are inclined to one another with dihedral angles varying between 38.3 (4) and 74.1 (4)°. In the crystal, molecules are linked via O-H...Cl hydrogen bonds involving one Cl- anion and the water molecule in the equatorial plane, forming an inversion dimer-like arrangement. The water molecule in the axial position is hydrogen-bonded to both Cl- anions. There are also a number of C-H...Cl hydrogen bonds present, forming a three-dimensional structure. All four alkyl chains are disordered over two positions with refined occupancy ratios of 0.395 (15):0.605 (15), 0.658 (14):0.342 (14), 0.332 (11):0.668 (11) and 0.622 (12):0.378 (12).

Related literature

For biological and pharmaceutical properties of imidazoles and imidazole-containing compounds, see: Roman et al. (2007[Roman, G., Riley, J. G., Vlahakis, J. Z., Kinobe, R. T., Brien, J. F., Nakatsu, K. & Szarek, W. A. (2007). Bioorg. Med. Chem. 15, 3225-3234.]); Nanterment et al. (2004[Nanterment, P. G., Barrow, J. C., Lindsley, S. R., Young, M., Mao, S., Carroll, S., Bailey, C., Bosserman, M., Colussi, D., McMasters, D. R., Vacca, J. P. & Selnick, H. G. (2004). Bioorg. Med. Chem. Lett. 14, 2141-2145.]); Congiu et al. (2008[Congiu, C., Cocco, M. T. & Onnis, V. (2008). Bioorg. Med. Chem. Lett. 18, 989-993.]); Venkatesan et al. (2008[Venkatesan, A. M., Agarwal, A., Abe, T., Ushirogochi, H. O., Santos, D., Li, Z., Francisco, G., Lin, Y. I., Peterson, P. J., Yang, Y., Weiss, W. J., Shales, D. M. & Mansour, T. S. (2008). Bioorg. Med. Chem. 16, 1890-1902.]); Bhatnagar et al. (2011[Bhatnagar, A., Sharma, P. K. & Kumar, N. (2011). Int. J. Pharm. Tech. Res. 3, 268-282.]); Puratchikody & Doble (2007[Puratchikody, A. & Doble, M. (2007). Bioorg. Med. Chem. Lett. 15, 1083-1090.]); Gaonkar et al. (2009[Gaonkar, S. L., Rai, K. M. L. & Shetty, N. S. (2009). Med. Chem. Res. 18, 221-230.]). For applications of imidazole and its derivatives in the construction of metal-organic frameworks, see: Huang et al. (2008[Huang, X.-F., Fu, D.-W. & Xiong, R.-G. (2008). Cryst. Growth Des. 8, 1795-1797.], 2011[Huang, Z.-J., Tang, J.-N., Luo, Z.-R., Wang, D.-Y. & Wei, H. (2011). Acta Cryst. E67, m408.]).

[Scheme 1]

Experimental

Crystal data
  • [Ni(C7H12N2)4(H2O)2]Cl2

  • Mr = 662.39

  • Monoclinic, P 21 /n

  • a = 8.533 (5) Å

  • b = 24.952 (5) Å

  • c = 17.641 (5) Å

  • [beta] = 101.277 (5)°

  • V = 3684 (3) Å3

  • Z = 4

  • Mo K[alpha] radiation

  • [mu] = 0.71 mm-1

  • T = 293 K

  • 0.30 × 0.30 × 0.25 mm

Data collection
  • Oxford Xcalibur diffractometer with Eos detector

  • Absorption correction: multi-scan (CrysAlis PRO; Oxford Diffraction, 2009[Oxford Diffraction (2009). CrysAlis CCD, CrysAlis RED and CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.]) Tmin = 0.790, Tmax = 0.816

  • 32409 measured reflections

  • 6451 independent reflections

  • 4027 reflections with I > 2[sigma](I)

  • Rint = 0.113

Refinement
  • R[F2 > 2[sigma](F2)] = 0.077

  • wR(F2) = 0.233

  • S = 1.04

  • 6451 reflections

  • 530 parameters

  • 707 restraints

  • H atoms treated by a mixture of independent and constrained refinement

  • [Delta][rho]max = 0.77 e Å-3

  • [Delta][rho]min = -0.69 e Å-3

Table 1
Hydrogen-bond geometry (Å, °)

D-H...A D-H H...A D...A D-H...A
O1-H1A...Cl2i 0.84 (4) 2.35 (4) 3.165 (4) 164 (7)
O1-H1B...Cl1 0.84 (4) 2.37 (4) 3.185 (5) 166 (4)
O2-H2A...Cl2 0.86 (4) 2.43 (4) 3.250 (4) 160 (5)
O2-H2B...Cl2i 0.84 (6) 2.30 (5) 3.127 (4) 169 (5)
C3-H3...Cl2 0.93 2.67 3.593 (6) 171
C4-H4...Cl2 0.93 2.70 3.565 (8) 155
C5-H5...Cl1ii 0.93 2.72 3.640 (8) 173
C9-H9...Cl1 0.93 2.65 3.566 (7) 170
C10-H10...Cl1 0.93 2.67 3.562 (7) 160
C11-H11...Cl1iii 0.93 2.79 3.722 (7) 177
Symmetry codes: (i) -x, -y+1, -z; (ii) [x-{\script{1\over 2}}, -y+{\script{1\over 2}}, z+{\script{1\over 2}}]; (iii) [x+{\script{1\over 2}}, -y+{\script{1\over 2}}, z+{\script{1\over 2}}].

Data collection: CrysAlis CCD (Oxford Diffraction, 2009[Oxford Diffraction (2009). CrysAlis CCD, CrysAlis RED and CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.]); cell refinement: CrysAlis CCD; data reduction: CrysAlis RED (Oxford Diffraction, 2009[Oxford Diffraction (2009). CrysAlis CCD, CrysAlis RED and CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.]); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012[Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849-854.]); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2009[Spek, A. L. (2009). Acta Cryst. D65, 148-155.]).


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: SU2624 ).


Acknowledgements

ASP and PSK thank the Department of Chemistry, Pondicherry University, for the single-crystal XRD instrumentation facility. KA thanks CSIR, New Delhi [Lr: No. 01 (2570)/12/EMR-II/3.4.2012], for financial support through a Major Research Project.

References

Bhatnagar, A., Sharma, P. K. & Kumar, N. (2011). Int. J. Pharm. Tech. Res. 3, 268-282.  [ChemPort]
Congiu, C., Cocco, M. T. & Onnis, V. (2008). Bioorg. Med. Chem. Lett. 18, 989-993.  [CrossRef] [PubMed] [ChemPort]
Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849-854.  [ISI] [CrossRef] [ChemPort] [details]
Gaonkar, S. L., Rai, K. M. L. & Shetty, N. S. (2009). Med. Chem. Res. 18, 221-230.  [ISI] [CrossRef] [ChemPort]
Huang, X.-F., Fu, D.-W. & Xiong, R.-G. (2008). Cryst. Growth Des. 8, 1795-1797.  [CSD] [CrossRef] [ChemPort]
Huang, Z.-J., Tang, J.-N., Luo, Z.-R., Wang, D.-Y. & Wei, H. (2011). Acta Cryst. E67, m408.  [CSD] [CrossRef] [details]
Nanterment, P. G., Barrow, J. C., Lindsley, S. R., Young, M., Mao, S., Carroll, S., Bailey, C., Bosserman, M., Colussi, D., McMasters, D. R., Vacca, J. P. & Selnick, H. G. (2004). Bioorg. Med. Chem. Lett. 14, 2141-2145.  [PubMed]
Oxford Diffraction (2009). CrysAlis CCD, CrysAlis RED and CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.
Puratchikody, A. & Doble, M. (2007). Bioorg. Med. Chem. Lett. 15, 1083-1090.  [ChemPort]
Roman, G., Riley, J. G., Vlahakis, J. Z., Kinobe, R. T., Brien, J. F., Nakatsu, K. & Szarek, W. A. (2007). Bioorg. Med. Chem. 15, 3225-3234.  [CrossRef] [PubMed] [ChemPort]
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [ChemPort] [details]
Spek, A. L. (2009). Acta Cryst. D65, 148-155.  [ISI] [CrossRef] [ChemPort] [details]
Venkatesan, A. M., Agarwal, A., Abe, T., Ushirogochi, H. O., Santos, D., Li, Z., Francisco, G., Lin, Y. I., Peterson, P. J., Yang, Y., Weiss, W. J., Shales, D. M. & Mansour, T. S. (2008). Bioorg. Med. Chem. 16, 1890-1902.  [CrossRef] [PubMed] [ChemPort]


Acta Cryst (2013). E69, m498-m499   [ doi:10.1107/S1600536813022496 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.